IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Zacks News
IDEXX Laboratories (IDXX) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
IDEXX Laboratories' (IDXX) first-quarter 2023 results are expected to reflect an impressive performance in the CAG segment despite inflationary impacts.
Zimmer Biomet (ZBH) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet's (ZBH) continued business recovery.
Masimo's (MASI) New FDA Approval to Improve Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) receipt of the FDA's clearance for the Rad-G with Temperature is expected to support clinicians in almost any care scenario.
3 Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
UnitedHealth (UNH) Buys Crystal Run to Boost Value-Based Care
by Zacks Equity Research
UnitedHealth Group (UNH) acquires Crystal Run, as per multiple reports. The move tends to offer enhanced value-based care across the Hudson Valley and lower Catskill region.
ALC vs. IDXX: Which Stock Is the Better Value Option?
by Zacks Equity Research
ALC vs. IDXX: Which Stock Is the Better Value Option?
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
Investors are optimistic about IDEXX's (IDXX) strength in the Companion Animal Group business.
The Zacks Analyst Blog Highlights UnitedHealth Group, Salesforce, Linde, IDEXX and Telefonica
by Zacks Equity Research
UnitedHealth Group, Salesforce, Linde, IDEXX and Telefonica are included in this Analyst Blog.
Top Research Reports for UnitedHealth Group, Salesforce & Linde
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Salesforce, Inc. (CRM) and Linde plc (LIN).
TMO or IDXX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
TMO vs. IDXX: Which Stock Is the Better Value Option?
Why Is Idexx (IDXX) Down 6.6% Since Last Earnings Report?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
Investors are optimistic about IDEXX's (IDXX) strong global performance.
IDEXX (IDXX) Global Sales, Instrument Placement Robust
by Zacks Equity Research
IDEXX (IDXX) continues to demonstrate solid growth globally, primarily aided by a gain in CAG and Water businesses.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Zacks Industry Outlook Highlights Edwards Lifesciences, IDEXX Laboratories and Hologic
by Zacks Equity Research
Edwards Lifesciences, IDEXX Laboratories and Hologic have been highlighted in this Industry Outlook article.
3 Medical Instruments Stocks to Buy Amid Improving Industry Trends
by Urmimala Biswas
The Zacks Medical - Instruments industry is growing on rising demand for digital health. EW, IDXX and HOLX are set to gain the most. Yet, the ongoing inflation, in the form of rising freight, raw material costs, is disrupting the trend.
Are Medical Stocks Lagging IDEXX Laboratories (IDXX) This Year?
by Zacks Equity Research
Here is how Idexx Laboratories (IDXX) and Aeterna Zentaris (AEZS) have performed compared to their sector so far this year.
Should You Invest in the First Trust Water ETF (FIW)?
by Zacks Equity Research
Sector ETF report for FIW
TMO vs. IDXX: Which Stock Is the Better Value Option?
by Zacks Equity Research
TMO vs. IDXX: Which Stock Is the Better Value Option?
Molina Healthcare (MOH) Q4 Earnings Beat on Solid Medicaid Unit
by Zacks Equity Research
Molina Healthcare's (MOH) fourth-quarter results benefit from its strong Medicaid and Medicare businesses. Management expects 2023 adjusted EPS at a minimum of $19.75.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Is AEterna Zentaris (AEZS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aeterna Zentaris (AEZS) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
IDEXX (IDXX) Q4 Earnings Beat Estimates, Margins Increases
by Zacks Equity Research
IDEXX's (IDXX) Q4 revenues are driven by continued benefits from expanding the global premium instrument installed base.
DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results are likely to reflect rising global awareness of its real-time CGM.
Idexx Laboratories (IDXX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 6.77% and 1.48%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?